Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elironrasib and daraxonrasib combinations with pembrolizumab with or without chemotherapy in RAS G12C-mutated NSCLC
NL-OMON59014Phase 1Recruiting
- Sponsor
- Revolution Medicines
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of elironrasib, daraxonrasib and pembrolizumab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (4 arms), sponsored by Revolution Medicines. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of treatment-emergent and treatment-related adverse events. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59014.